RECAL®: A New Tool for Disease Detection and Biomolecular Imaging

Information

  • Research Project
  • 9464448
  • ApplicationId
    9464448
  • Core Project Number
    R43GM126577
  • Full Project Number
    1R43GM126577-01
  • Serial Number
    126577
  • FOA Number
    PA-16-302
  • Sub Project Id
  • Project Start Date
    4/1/2018 - 7 years ago
  • Project End Date
    9/30/2018 - 7 years ago
  • Program Officer Name
    SAMMAK, PAUL J
  • Budget Start Date
    4/1/2018 - 7 years ago
  • Budget End Date
    9/30/2018 - 7 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
  • Award Notice Date
    3/30/2018 - 7 years ago
Organizations

RECAL®: A New Tool for Disease Detection and Biomolecular Imaging

Project Summary / Abstract We envision developing a new ultrasensitive detection platform that combines a recombinant protein with a unique imaging media that results in a luminescent protein that is non-bleaching and non-blinking. The excitation and emission wavelengths of this protein can be tuned with the choice of imaging media and span much of the visible and near infrared regions of the electromagnetic. We will refer to this new platform as RECAL®. RECAL® emits light as phosphorescence, but its unique properties result in an overall luminescence intensity that rivals and surpasses many fluorescent organic molecules and can be engineered into a luminescent upconversion probes in which IR excitation will lead to visible luminescence. This will surely allow for the effective use of RECAL® as a medical diagnostic tool in tissue, blood, and urine samples or environmental / homeland security devices to name but a few. This proposal has three aims: Aim 1. Develop the RECAL® into a microscale ELISA-based medical diagnostic kit for markers associated with liver function and compare its superior sensitivity and marketability to that of state-of-the art ELISA-based medical diagnostic kits in the current market. Aim 2. Test the feasibility of using RECAL® as a recombinant in vivo imaging technology and exploit its long luminescent lifetime and photochemical stability to suppress unwanted background in order to increase its sensitivity over existing GFP fusion technologies. Aim 3. Exploit the unique photophysics of associated with RECAL® to develop biomolecular imaging technology that absorbs multiple IR photons resulting in visible luminescence. Our goal is to develop commercially viable RECAL® products that will have far reaching benefits for medical diagnostics, biomedical research, homeland security, and ultimately human health.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    150000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:150000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHOTON BIOSCIENCES, LLC
  • Organization Department
  • Organization DUNS
    080575565
  • Organization City
    PULLMAN
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    991632751
  • Organization District
    UNITED STATES